receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	The frequency of neutropenia	15707	15793	The frequency of neutropenia was higher in the PE arm than in the FEC arm (P = 0.031).
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	The clinical response rates	1216	1341	The overall clinical response rate was significantly higher in the PE arm than in the FEC arm (76.06% vs. 59.95%, P = 0.001).
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	pCR (pCR in both the breast and lymph nodes) rates	1485	1557	the pCR rate was similar in the two arms (10.61% vs. 12.31%, P = 0.665).
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	The clinical response rates	-1	-1	The clinical response rates were significantly higher in the PE arm than in the FEC arm (76.55% vs. 56.95%, P = 0.001).
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	the post-chemotherapy pathologic T and N stages	1342	1475	Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm (P < 0.001).
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	pCR (pCR in both the breast and lymph nodes) rates	15130	15430	However, no significant differences between the FEC and PE arms were observed in the overall pCR (pCR in both the breast and lymph nodes) rates (10.61% vs. 12.31%, P = 0.665), the breast pCR rates (13.64% vs. 16.92%, P = 0.460), or regional lymph node pCR rates (34.85% vs. 39.23%, P = 0.463).Table 5
receive 4–6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide (FEC) regimen	weekly paclitaxel–epirubicin (PE) regimen	The frequency of neutropenia	1678	1821	Most adverse events were comparable in both arms, with more severe neutropenia in the PE arm than in the FEC arm (11.97% vs. 5.96%, P = 0.031).
